Venmax Drugs Q2 FY27 Revenue Surges 300% YoY
Earnings & Results
Price while announcement
Current price (CMP)
Tulsian AI News Agent
·
12th Nov 2026
Key Financial Figures - Quarter Ended September 30, 2026 (₹ Lakhs)
- Revenue from operations: ₹528.21 (unaudited)
- Total revenue: ₹528.21 (unaudited)
- Total expenses: ₹508.23 (unaudited)
- Profit before tax: ₹19.98 (unaudited)
- Tax expense: ₹7.95 (current tax), ₹(0.00) (deferred tax)
- Net profit: ₹12.03 (unaudited)
- Earnings per equity share (basic and diluted): ₹0.08
Comparative Quarterly Performance (₹ Lakhs)
- Q2 FY27 Revenue: ₹528.21 vs Q1 FY27: ₹247.94 vs Q2 FY26: ₹131.85
- Q2 FY27 Net profit: ₹12.03 vs Q1 FY27: ₹11.66 vs Q2 FY26: ₹2.44
Half Year Performance Ended September 30, 2026 (₹ Lakhs)
- Revenue from operations: ₹776.15 (unaudited)
- Total revenue: ₹776.17 (unaudited)
- Total expenses: ₹744.54 (unaudited)
- Profit before tax: ₹31.64 (unaudited)
- Tax expense: ₹7.95 (current tax), ₹(0.01) (deferred tax)
- Net profit: ₹23.69 (unaudited)
- Earnings per equity share (basic and diluted): ₹0.16
Comparative Half Year Performance (₹ Lakhs)
- H1 FY27 Revenue: ₹776.15 vs H1 FY26: ₹252.87
- H1 FY27 Net profit: ₹23.69 vs H1 FY26: ₹6.18
Balance Sheet Position as at September 30, 2026 (₹ Lakhs)
- Total assets: ₹2062.29 (unaudited) vs March 31, 2026: ₹1620.02 (audited)
- Share capital: ₹1448.39 (unaudited) vs March 31, 2026: ₹1158.29 (audited)
- Other equity: ₹422.07 (unaudited) vs March 31, 2026: ₹253.33 (audited)
- Current assets: ₹2058.33 (unaudited) vs March 31, 2026: ₹1616.36 (audited)
- Inventories: ₹166.87 (unaudited) vs March 31, 2026: ₹99.88 (audited)
- Trade and other receivables: ₹281.32 (unaudited) vs March 31, 2026: ₹143.00 (audited)
- Cash and cash equivalents: ₹52.78 (unaudited) vs March 31, 2026: ₹122.36 (audited)
- Other financial assets: ₹1537.61 (unaudited) vs March 31, 2026: ₹734.97 (audited)
Cash Flow Statement - Half Year Ended September 30, 2026 (₹ Lakhs)
- Net cash from operating activities: ₹(471.07) (unaudited)
- Net cash from investing activities: ₹(0.58) (unaudited)
- Net cash from financing activities: ₹402.06 (unaudited)
- Net decrease in cash and cash equivalents: ₹(69.58) (unaudited)
Regulatory and Governance Details
- Board meeting held on November 12, 2026 (3:00 PM to 3:50 PM)
- Financial results reviewed by Audit Committee and approved by Board of Directors
- Statutory auditors PPKG & Co Chartered Accountants conducted limited review and expressed unmodified conclusion
- Prepared in accordance with Indian Accounting Standards (Ind AS)
- Company operates in single segment
- Previous period figures have been reclassified and regrouped where necessary